REPORT
3 new drugs to watch this fall
Are these new gene therapies worth the price?
By Sumit Dutta, MD, Chief Medical Officer at Optum Rx | Published: October 2022
Welcome to the fall edition of Drugs to Watch.
As the year begins to close, we highlight three essential pipeline drugs with an expected U.S. Food and Drug Administration (FDA) decision.
Two of the three drugs discussed here have an Orphan Drug designation, while the third was granted Priority Review designation. In today's market, we are seeing new orphan drugs more frequently and expect this trend to continue. However, you may be surprised by the price tag.
The drugs in this report include treatments for:
- Kidney disease
- Inherited bleeding disorder
- Eye disease
Don't want to read the full report? Download the brief summary.
Related content
Articles and blogs
4 more psoriasis drugs on the way
Psoriasis costs up 40% in 5 years. Will these drugs help?
Articles and blogs
Reality check: New drugs will cost more
The trend toward complex biologic drugs continues